Non-Alcoholic Fatty Liver Disease Treatment Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Epidemiology, Medication, NDA Approvals, Pipeline, Therapeutics and Companies by DelveInsight

(Albany, USA) DelveInsight's "Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Non-Alcoholic Fatty Liver Disease, historical and forecasted epidemiology as well as the Non-Alcoholic Fatty Liver Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The NAFLD market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted NAFLD market size from 2020 to 2034, segmented by seven major markets. The NAFLD Market Report also covers current NAFLD treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the NAFLD market.

To Know in detail about the Non-Alcoholic Fatty Liver Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Alcoholic Fatty Liver Disease Market Forecast
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Non-Alcoholic Fatty Liver Disease Market Report:
• The Non-Alcoholic Fatty Liver Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In December 2024, Galectin Therapeutics revealed the results from its global clinical trial, NAVIGATE, which assessed the effectiveness of belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
• In October 2024, PharmaIN Corporation announced that it will present interim results from its ongoing Phase I clinical trial of PHIN-214, its leading candidate, for the prevention and treatment of decompensated cirrhosis.
• The existing pipeline for NASH comprises a wide array of medications. FXR agonists, FGF21 stimulants, FGF19 analogs, glucagon-like peptide-1 (GLP-1) agonists, peroxisome proliferator-activated receptor (PPAR) regulators, THR-β agonists, and several others are among the prominent classes for this condition.
• According to American Liver Foundation (n.d.), NAFLD is the most common chronic liver condition in the United States. It's estimated that about 25% of adults in the U.S. have NAFLD. Of those with NAFLD, about 20% have NASH (5% of adults in the US). Most people with NAFLD have simply fatty live
• According to the study conducted by Foschi et al. (2019), titled, "Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study," the prevalence of non-alcoholic fatty liver disease (NAFLD) was 0.46 (0.41 to 0.51) vs. 0.22 (0.21 to 0.24) in citizens with than in those without altered liver enzymes
• Key Non-Alcoholic Fatty Liver Disease Companies: Inventiva Pharma, Eli Lilly and Company, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., Novo Nordisk A/S, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Madrigal Pharmaceuticals, Altimmune, Inc., GlaxoSmithKline, Axcella Health, Inc, AstraZeneca, Gannex Pharma Co., Ltd., Dexa Medica Group, Boehringer Ingelheim, Can-Fite BioPharma, Rivus Pharmaceuticals, Inc., Regeneron Pharmaceuticals, MediciNova, and others
• Key Non-Alcoholic Fatty Liver Disease Therapies: Lanifibranor, Tirzepatide, MGL-3196, Semaglutide, Obeticholicacid (OCA), Pegozafermin, DA-1241, NNC0194 0499, J2H-1702, HSK31679, Resmetirom, Pemvidutide, GSK4532990, AXA1125, AZD9550, 2mg of ASC41, Proliverenol, Survodutide, Namodenoson, HU6, ALN-HSD, MN-001, and others
• The Non-Alcoholic Fatty Liver Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Alcoholic Fatty Liver Disease pipeline products will significantly revolutionize the Non-Alcoholic Fatty Liver Disease market dynamics.

Non-Alcoholic Fatty Liver Disease Overview
Non-Alcoholic Fatty Liver Disease (NAFLD) is a common liver disorder characterized by excess fat accumulation in the liver, not caused by alcohol consumption. It affects millions worldwide and is strongly associated with obesity, type 2 diabetes, metabolic syndrome, and insulin resistance. NAFLD encompasses a spectrum of conditions, ranging from simple fatty liver (steatosis) to the more severe form, non-alcoholic steatohepatitis (NASH), which involves liver inflammation and damage, potentially leading to fibrosis, cirrhosis, or liver cancer.

Most individuals with NAFLD experience no symptoms, but some may have fatigue, mild upper right abdominal discomfort, or liver enzyme abnormalities detected through blood tests. Diagnosis typically involves imaging techniques like ultrasound, MRI, or FibroScan, and in some cases, a liver biopsy to assess disease severity.

There are no approved medications for NAFLD, so treatment primarily focuses on lifestyle modifications. Weight loss through diet and exercise is the most effective strategy, with a goal of reducing body weight by 5-10%. Managing associated conditions such as diabetes, hypertension, and dyslipidemia is crucial. Emerging therapies, including drugs targeting liver fat metabolism and inflammation, are under investigation.

Early detection and proactive management can prevent disease progression and reduce the risk of liver-related complications.

Get a Free sample for the Non-Alcoholic Fatty Liver Disease Market Report -
https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Non-Alcoholic Fatty Liver Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Non-Alcoholic Fatty Liver Disease Epidemiology Segmentation:
The Non-Alcoholic Fatty Liver Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Non-Alcoholic Fatty Liver Disease
• Prevalent Cases of Non-Alcoholic Fatty Liver Disease by severity
• Gender-specific Prevalence of Non-Alcoholic Fatty Liver Disease
• Diagnosed Cases of Episodic and Chronic Non-Alcoholic Fatty Liver Disease

Download the report to understand which factors are driving Non-Alcoholic Fatty Liver Disease epidemiology trends @ Non-Alcoholic Fatty Liver Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Non-Alcoholic Fatty Liver Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Alcoholic Fatty Liver Disease market or expected to get launched during the study period. The analysis covers Non-Alcoholic Fatty Liver Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-Alcoholic Fatty Liver Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Non-Alcoholic Fatty Liver Disease Therapies and Key Companies
• Lanifibranor: Inventiva Pharma
• Tirzepatide: Eli Lilly and Company
• MGL-3196: Madrigal Pharmaceuticals, Inc.
• Obeticholicacid (OCA): Intercept Pharmaceuticals
• Pegozafermin: 89bio, Inc.
• Semaglutide: Novo Nordisk A/S
• DA-1241: NeuroBo Pharmaceuticals Inc
• NNC0194 0499: Novo Nordisk A/S
• J2H-1702: J2H Biotech
• HSK31679: Haisco Pharmaceutical
• Resmetirom: Madrigal Pharmaceuticals
• Pemvidutide: Altimmune, Inc.
• GSK4532990: GlaxoSmithKline
• AXA1125: Axcella Health, Inc
• AZD9550: AstraZeneca
• 2mg of ASC41: Gannex Pharma Co., Ltd.
• Proliverenol: Dexa Medica Group
• Survodutide: Boehringer Ingelheim
• Namodenoson: Can-Fite BioPharma
• HU6: Rivus Pharmaceuticals, Inc.
• ALN-HSD: Regeneron Pharmaceuticals
• MN-001: MediciNova

Discover more about therapies set to grab major Non-Alcoholic Fatty Liver Disease market share @ Non-Alcoholic Fatty Liver Disease Treatment Market
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Non-Alcoholic Fatty Liver Disease Market Strengths
• Growing research activities and multiple clinical trials ongoing for NASH, suggests that the number of drugs is being developed, that will strengthen the market

Non-Alcoholic Fatty Liver Disease Market Opportunities
• Lucrative opportunities for the market growth in United States, owing to presence of large pool of patients suffering from NASH

Scope of the Non-Alcoholic Fatty Liver Disease Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Non-Alcoholic Fatty Liver Disease Companies: Inventiva Pharma, Eli Lilly and Company, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., Novo Nordisk A/S, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Madrigal Pharmaceuticals, Altimmune, Inc., GlaxoSmithKline, Axcella Health, Inc, AstraZeneca, Gannex Pharma Co., Ltd., Dexa Medica Group, Boehringer Ingelheim, Can-Fite BioPharma, Rivus Pharmaceuticals, Inc., Regeneron Pharmaceuticals, MediciNova, and others
• Key Non-Alcoholic Fatty Liver Disease Therapies: Lanifibranor, Tirzepatide, MGL-3196, Semaglutide, Obeticholicacid (OCA), Pegozafermin, DA-1241, NNC0194 0499, J2H-1702, HSK31679, Resmetirom, Pemvidutide, GSK4532990, AXA1125, AZD9550, 2mg of ASC41, Proliverenol, Survodutide, Namodenoson, HU6, ALN-HSD, MN-001, and others
• Non-Alcoholic Fatty Liver Disease Therapeutic Assessment: Non-Alcoholic Fatty Liver Disease current marketed and Non-Alcoholic Fatty Liver Disease emerging therapies
• Non-Alcoholic Fatty Liver Disease Market Dynamics: Non-Alcoholic Fatty Liver Disease market drivers and Non-Alcoholic Fatty Liver Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Non-Alcoholic Fatty Liver Disease Unmet Needs, KOL's views, Analyst's views, Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement

To know more about Non-Alcoholic Fatty Liver Disease companies working in the treatment market, visit @ Non-Alcoholic Fatty Liver Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Non-Alcoholic Fatty Liver Disease Market Report Introduction
2. Executive Summary for Non-Alcoholic Fatty Liver Disease
3. SWOT analysis of Non-Alcoholic Fatty Liver Disease
4. Non-Alcoholic Fatty Liver Disease Patient Share (%) Overview at a Glance
5. Non-Alcoholic Fatty Liver Disease Market Overview at a Glance
6. Non-Alcoholic Fatty Liver Disease Disease Background and Overview
7. Non-Alcoholic Fatty Liver Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Non-Alcoholic Fatty Liver Disease
9. Non-Alcoholic Fatty Liver Disease Current Treatment and Medical Practices
10. Non-Alcoholic Fatty Liver Disease Unmet Needs
11. Non-Alcoholic Fatty Liver Disease Emerging Therapies
12. Non-Alcoholic Fatty Liver Disease Market Outlook
13. Country-Wise Non-Alcoholic Fatty Liver Disease Market Analysis (2019-2032)
14. Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement of Therapies
15. Non-Alcoholic Fatty Liver Disease Market Drivers
16. Non-Alcoholic Fatty Liver Disease Market Barriers
17. Non-Alcoholic Fatty Liver Disease Appendix
18. Non-Alcoholic Fatty Liver Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Phosphoglucomutase Pgm 1 Deficiency Market: https://www.delveinsight.com/report-store/phosphoglucomutase-pgm-1-deficiency-market
• Polypoidal Choroidal Vasculopathy Market: https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market
• Tay-sachs Disease Or Gm2 Gangliosidosis Market: https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Graft Versus Host Disease Market: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/report-store.php
AACR Conference Coverage: https://www.delveinsight.com/aacr-annual-meeting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.